Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients.

The phosphoinositide 3-kinase (PI3K/Akt) pathway is activated in acute myelogenous leukemia (AML) and is promising for targeted inhibition. Ninety-two patients with primary AML were analyzed for PI3K/Akt constitutive activation. Fifty percent of the patients presented with constitutive PI3K activation (PI3K (+)). No difference was observed between PI3K (+) and PI3K (-) groups concerning age, sex, white blood cell count, lactate dehydrogenase (LDH) level, bone marrow blast cells, French-American-British (FAB) classification, cytogenetics, RAS or nucleophosmin (NPM) mutations. Slightly more FLT3-ITD was detected in the PI3K (-) group (P = .048). The complete remission rate was similar between the 2 groups. With a median follow-up of 26 months, we observed for PI3K (+) and PI3K (-) patients, respectively, 56% and 33% overall survival (P = .001) and 72% and 41% relapse-free survival (P = .001). Constitutive PI3K/Akt activity is a favorable prognosis factor in AML, even after adjustment for FLT3-ITD, and may confer a particular sensitivity to chemotherapy. A better understanding of the downstream effectors of the PI3K/Akt pathway is needed before targeting in AML.

[1]  J. Tamburini,et al.  Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110δ mutations , 2006, Leukemia.

[2]  Steven M Kornblau,et al.  Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. , 2004, Blood.

[3]  C. Billottet,et al.  A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. , 2006, Oncogene.

[4]  C. Sawyers.  Will kinase inhibitors have a dark side? , 2006, The New England journal of medicine.

[5]  E. Solary,et al.  Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. , 2005, Blood.

[6]  B Asselain,et al.  A Semiparametric Approach for the Two‐Sample Comparison of Survival Times with Long‐Term Survivors , 2001, Biometrics.

[7]  A. Khwaja,et al.  PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPkinase and p53 pathways , 2005, Leukemia.

[8]  O. Bernard,et al.  Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotype , 2006, Leukemia.

[9]  D Puthier,et al.  High incidence of N and K‐Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis , 2001, Human mutation.

[10]  M. Carroll,et al.  Survival of acute myeloid leukemia cells requires PI3 kinase activation. , 2003, Blood.

[11]  H. Kaneko,et al.  Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.

[12]  J. Cheong,et al.  Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable , 2003, Leukemia.

[13]  E. Solary,et al.  Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia , 2005 .

[14]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[15]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[16]  A. Toker,et al.  Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. , 2005, Molecular cell.

[17]  J. Tamburini,et al.  Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry. , 2006, Haematologica.